Barclays analyst Gena Wang lowered the firm’s price target on Intellia Therapeutics (NTLA) to $14 from $24 and keeps an Overweight rating on the shares. The company’s Q3 report include the death of the Hy’s Law case patient, which makes regulatory milestone timing unclear, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Cautious Hold Rating on Intellia Therapeutics Amid Safety Concerns and Regulatory Uncertainty
- Intellia Therapeutics downgraded to Underweight from Neutral at JPMorgan
- Intellia Therapeutics: Buy Rating Affirmed Amid HAE Program Optimism Despite ATTR Setback
- Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings
- Intellia Therapeutics: Buy Rating Backed by MAGNITUDE Trial Resumption and Promising Data Releases